[Viva] Fwd: aidsmap news: News from the Southern African HIV Clinicians Society conference, 18 December 2012
Margarite Sanchez
margaritesanchez at gmail.com
Tue Dec 18 11:54:19 PST 2012
fyi
News out of South Africa.
---------- Forwarded message ----------
From: <aidsmapnews at nam.org.uk>
Date: Tue, Dec 18, 2012 at 3:26 AM
Subject: aidsmap news: News from the Southern African HIV Clinicians
Society conference, 18 December 2012
To: margaritesanchez at gmail.com
Having problems reading this email? View it in your browser
>><http://www.aidsmap.com/page/2560024/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
[image: aidsmap
news]<http://www.aidsmap.com/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
18 December 2012
<http://www.aidsmap.com/donate?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
News from the Southern African HIV Clinicians Society conference
Low-dose stavudine study debated between South African researchers and
activists<http://www.aidsmap.com/Low-dose-stavudine-study-debated-between-South-African-researchers-and-activists/page/2558668/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
A proposed trial of low-dose stavudine (also known as d4T) sparked a heated
debate between South African researchers and activists at the opening of
the first Southern African HIV Clinicians Society Conference held in Cape
Town.
Read more >><http://www.aidsmap.com/Low-dose-stavudine-study-debated-between-South-African-researchers-and-activists/page/2558668/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Study of South African sex worker characteristics could assist in informing
policy decisions<http://www.aidsmap.com/Study-of-South-African-sex-worker-characteristics-could-assist-in-informing-policy-decisions/page/2557202/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Male and transgender sex workers in South Africa are at particularly high
risk of HIV infection and have significant unmet prevention needs,
according to results of a large multi-site study presented last month at
the Southern African HIV Clinicians Society conference in Cape Town.
Read more >><http://www.aidsmap.com/Study-of-South-African-sex-worker-characteristics-could-assist-in-informing-policy-decisions/page/2557202/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Out-of-clinic adherence club for delivery of ARVs shows better retention
than standard of
care<http://www.aidsmap.com/Out-of-clinic-adherence-club-for-delivery-of-ARVs-shows-better-retention-than-standard-of-care/page/2557041/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
An out-of-clinic model of HIV treatment delivery in South Africa has shown
superior results to the standard in-clinic delivery of antiretrovirals
(ARVs), according to results of an evaluation presented by Dr Gilles Van
Cutsem at the Southern African HIV Clinicians Society conference in Cape
Town.
Read more >><http://www.aidsmap.com/Out-of-clinic-adherence-club-for-delivery-of-ARVs-shows-better-retention-than-standard-of-care/page/2557041/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
More news from AASLD 2012
Adding pegylated interferon to entecavir improves hepatitis B treatment
response
<http://www.aidsmap.com/Adding-pegylated-interferon-to-entecavir-improves-hepatitis-B-treatment-response/page/2559274/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Intensifying entecavir (*Baraclude*) treatment for hepatitis B by adding
pegylated interferon lowers HBV viral load and increases the likelihood of
hepatitis B "e" antigen (HBeAg) loss, according to a presentation at the
63rd annual meeting of the American Association for the Study of Liver
Diseases (AASLD) last month in Boston. A related study found that hepatitis
B surface antigen (HBsAg) levels during treatment can predict response.
Read more >><http://www.aidsmap.com/Adding-pegylated-interferon-to-entecavir-improves-hepatitis-B-treatment-response/page/2559274/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Adherence to hepatitis C treatment: unravelling the
complexities<http://www.aidsmap.com/Adherence-to-hepatitis-C-treatment-unravelling-the-complexities/page/2557193/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Successful adherence to hepatitis C treatment may require physicians and
care teams to address a wide range of factors, according to research from
the United States and Germany presented at the 63rd annual meeting of the
American Association for the Study of Liver Diseases (AASLD) in Boston.
Read more >><http://www.aidsmap.com/Adherence-to-hepatitis-C-treatment-unravelling-the-complexities/page/2557193/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Is a simple sofosbuvir plus ribavirin regimen suitable for
difficult-to-treat hepatitis C
patients?<http://www.aidsmap.com/Is-a-simple-sofosbuvir-plus-ribavirin-regimen-suitable-for-difficult-to-treat-hepatitis-C-patients/page/2558648/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
An all-oral dual regimen of sofosbuvir (GS-7977) plus full-dose ribavirin
was well-tolerated and produced four-week post-treatment sustained response
in approximately three-quarters of previously untreated genotype 1 chronic
hepatitis C patients in an inner-city pilot study, researchers reported at
the 63rd annual meeting of the American Association for the Study of Liver
Diseases (AASLD) in Boston. Reducing the ribavirin dose, however, lowered
response rates.
Read more >><http://www.aidsmap.com/Is-a-simple-sofosbuvir-plus-ribavirin-regimen-suitable-for-difficult-to-treat-hepatitis-C-patients/page/2558648/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Hepatitis C patients with cirrhosis respond well to boceprevir or
telaprevir with careful
monitoring<http://www.aidsmap.com/Hepatitis-C-patients-with-cirrhosis-respond-well-to-boceprevir-or-telaprevir-with-careful-monitoring/page/2557617/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Real-world experience in the French early-access CUPIC cohort shows that
hepatitis C patients with advanced liver damage can achieve good response
to interferon-based triple-therapy including boceprevir (*Victrelis*) or
telaprevir (*Incivo*), researchers reported at the 63rd annual meeting of
the American Association for the Study of Liver Diseases (AASLD).
Read more >><http://www.aidsmap.com/Hepatitis-C-patients-with-cirrhosis-respond-well-to-boceprevir-or-telaprevir-with-careful-monitoring/page/2557617/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Brivanib fails to match sorafenib for liver cancer, but tivantinib looks
promising<http://www.aidsmap.com/Brivanib-fails-to-match-sorafenib-for-liver-cancer-but-tivantinib-looks-promising/page/2557612/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
The investigational cancer drug brivanib did not significantly increase
survival for people with hepatocellular carcinoma over existing standard
therapy, researchers reported at the 63rd annual meeting of the American
Association for the Study of Liver Diseases (AASLD) in Boston. But another
drug, tivantinib, did appear beneficial for a subset of patients.
Read more >><http://www.aidsmap.com/Brivanib-fails-to-match-sorafenib-for-liver-cancer-but-tivantinib-looks-promising/page/2557612/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Telaprevir and VX-222 pair well in interferon-free regimen, VX-135 on the
horizon<http://www.aidsmap.com/Telaprevir-and-VX-222-pair-well-in-interferon-free-regimen-VX-135-on-the-horizon/page/2557100/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
An all-oral regimen of telaprevir, VX-222 and ribavirin for 12 weeks was
generally well-tolerated and produced sustained virological response in
approximately 70% of previously untreated chronic hepatitis C patients,
according to findings from the ZENITH study presented at the 63rd annual
meeting of the American Association for the Study of Liver Diseases (AASLD).
Read more >><http://www.aidsmap.com/Telaprevir-and-VX-222-pair-well-in-interferon-free-regimen-VX-135-on-the-horizon/page/2557100/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
AASLD 2012<http://www.aidsmap.com/AASLD-2012/page/2547747/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
For all our news coverage of this conference, visit the conference news
pages of our website.
Read more >><http://www.aidsmap.com/AASLD-2012/page/2547747/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Other recent news from aidsmap
Traditional risk factors strongest predictors of sub-clinical
cardiovascular disease in people about to start HIV
therapy<http://www.aidsmap.com/Traditional-risk-factors-strongest-predictors-of-sub-clinical-cardiovascular-disease-in-people-about-to-start-HIV-therapy/page/2558866/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Sub-clinical cardiovascular disease in people with HIV is more strongly
associated with traditional risk factors for heart disease rather than
inflammation or HIV-related parameters, US research published in the online
edition of *AIDS* suggests.
Read more >><http://www.aidsmap.com/Traditional-risk-factors-strongest-predictors-of-sub-clinical-cardiovascular-disease-in-people-about-to-start-HIV-therapy/page/2558866/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
HIV and hepatitis C co-infection increases the risk of cognitive
impairment<http://www.aidsmap.com/HIV-and-hepatitis-C-co-infection-increases-the-risk-of-cognitive-impairment/page/2557928/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Co-infection with HIV and hepatitis C is associated with an increased risk
of cognitive impairment, according to research published in the online
edition of the *Journal of Acquired Immune Deficiency Syndromes*.
Read more >><http://www.aidsmap.com/HIV-and-hepatitis-C-co-infection-increases-the-risk-of-cognitive-impairment/page/2557928/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Exclusive breastfeeding hampered by infant illnesses, follow up of mothers
with HIV shows<http://www.aidsmap.com/Exclusive-breastfeeding-hampered-by-infant-illnesses-follow-up-of-mothers-with-HIV-shows/page/2557107/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Only one third of women counselled to exclusively breast feed for six
months in the Kesho Bora study were able to sustain the practice for at
least three months, indicating the challenges of implementing infant
feeding advice for prevention of mother-to-child HIV transmission,
researchers report in the advance online edition of the *Journal of
Acquired Immune Deficiency Syndromes*.
Read more >><http://www.aidsmap.com/Exclusive-breastfeeding-hampered-by-infant-illnesses-follow-up-of-mothers-with-HIV-shows/page/2557107/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Diet quality predicts HIV progression and death in resource-poor
settings<http://www.aidsmap.com/Diet-quality-predicts-HIV-progression-and-death-in-resource-poor-settings/page/2555254/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
The more diverse and nutrient-rich the diet before starting antiretroviral
treatment (ART), the less severe HIV disease progression is, and the less
likely death occurs, researchers report in the advance online edition of
the *Journal of Acquired Immune Deficiency Syndromes*. The study involved a
cohort of over 800 people living with HIV in Uganda.
Read more >><http://www.aidsmap.com/Diet-quality-predicts-HIV-progression-and-death-in-resource-poor-settings/page/2555254/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Couples HIV testing and counselling prompts rapid switch to consistent
condom use in South African
study<http://www.aidsmap.com/Couples-HIV-testing-and-counselling-prompts-rapid-switch-to-consistent-condom-use-in-South-African-study/page/2555269/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
HIV testing and counselling of couples quickly led to consistent condom use
among serodiscordant couples in stable relationships in South Africa,
researchers report in the advance online edition of the *Journal of
Acquired Immune Deficiency Syndromes*.
Read more >><http://www.aidsmap.com/Couples-HIV-testing-and-counselling-prompts-rapid-switch-to-consistent-condom-use-in-South-African-study/page/2555269/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Swiss research identifies factors associated with use of non-recommended
HIV therapy
<http://www.aidsmap.com/Swiss-research-identifies-factors-associated-with-use-of-non-recommended-HIV-therapy/page/2557058/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
New Swiss research shows the importance of observing antiretroviral
treatment guidelines, even in people who have well-controlled HIV
infection. Published in the online edition of the *Journal of Acquired
Immune Deficiency Syndromes*, the study demonstrated that toxicities and
concerns about long-term side-effects were common reasons for switching to
recommended treatment. CD4 cell count, viral load and adherence either
remained stable or improved after the treatment change.
Read more >><http://www.aidsmap.com/Swiss-research-identifies-factors-associated-with-use-of-non-recommended-HIV-therapy/page/2557058/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
'Real-world' evidence shows that antiretroviral therapy reduces risk of HIV
transmission in heterosexual
couples<http://www.aidsmap.com/Real-world-evidence-shows-that-antiretroviral-therapy-reduces-risk-of-HIV-transmission-in-heterosexual-couples/page/2557243/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
A study conducted in China has provided 'real-world' evidence of the impact
of antiretroviral therapy on the risk of transmission in heterosexual
couples. Published in *The Lancet*, the retrospective research showed that
the risk of HIV transmission was reduced by 26% in serodiscordant couples
where the HIV-infected partner was taking antiretroviral therapy when
compared to serodiscordant couples where the HIV-positive partner remained
treatment naive.
Read more >><http://www.aidsmap.com/Real-world-evidence-shows-that-antiretroviral-therapy-reduces-risk-of-HIV-transmission-in-heterosexual-couples/page/2557243/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
FDA Advisory Committee recommends accelerated approval of bedaquiline for
drug-resistant TB<http://www.aidsmap.com/FDA-Advisory-Committee-recommends-accelerated-approval-of-bedaquiline-for-drug-resistant-TB/page/2557073/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Bedaquiline, the first agent in a new class of TB drug, has been
recommended for accelerated approval by the Anti-Infective Drugs Advisory
Committee of the United States Food and Drug Administration (FDA).
Read more >><http://www.aidsmap.com/FDA-Advisory-Committee-recommends-accelerated-approval-of-bedaquiline-for-drug-resistant-TB/page/2557073/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Editors' picks from other sources
Rapid test for HIV approved in
Australia<http://www.aidsmap.com/Aggregator.ashx?type=bulletin&url=http%3a%2f%2fwww.theaustralian.com.au%2fnews%2frapid-test-for-hiv-approved-in-australia%2fstory-e6frg6n6-1226538493754&utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
from The Australian
Federal Health Minister Tanya Plibersek announced the Therapeutic Goods
Administration (TGA) had approved for marketing the Alere Determine Combo
HIV 1/2 Ag/Ab test, which will give people a preliminary result within 30
minutes.
Hepatitis C sexual transmission is rare among monogamous heterosexual
couples<http://www.aidsmap.com/Aggregator.ashx?type=bulletin&url=http%3a%2f%2fwww.hivandhepatitis.com%2fhepatitis-c%2fhepatitis-c-topics%2fhcv-prevention%2f3904-hepatitis-c-sexual-transmission-is-rare-among-monogamous-heterosexual-couples&utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
from HIVandHepatitis.com
Transmission of hepatitis C virus (HCV) between long-term, monogamous,
heterosexual partners can potentially occur, but appears to be very
uncommon, according to a study of 500 couples described in the November 23,
2012, advance online edition of *Hepatology*. Furthermore, the analysis
failed to find a link between HCV transmission and any specific sexual
activities.
Childhood HIV risks becoming neglected disease as fewer children born with
HIV, experts warn<http://www.aidsmap.com/Aggregator.ashx?type=bulletin&url=http%3a%2f%2fglobalhealth.kff.org%2fDaily-Reports%2f2012%2fDecember%2f03%2fGH-120312-Childhood-HIV.aspx%3futm_source%3dfeedburner%26utm_medium%3dfeed%26utm_campaign%3dFeed%3a%2bkff%2fkdghprhiv%2b(Kaiser%2bDaily%2bGlobal%2bHealth%2bPolicy%2bReport%2b-%2bHIV%2fAIDS)&utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
from Kaiser Daily Global Health Policy Report
Because fewer children are born with the virus, drug companies no longer
have an incentive to manufacture treatments – childhood HIV might become a
neglected disease.
The latest word on hormonal contraception and HIV
<http://www.aidsmap.com/Aggregator.ashx?type=bulletin&url=http%3a%2f%2fwww.plusnews.org%2fReport%2f96973%2fHIV-AIDS-The-latest-word-on-hormonal-contraception-and-HIV&utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
from IRIN Plus News
In early 2012, the UN World Health Organization (WHO) announced it could
not conclusively determine whether hormonal contraceptive injections
increased the risk of HIV transmission. Almost a year later, WHO is still
struggling to communicate clear guidance for women using injectable
contraceptives, who are largely in the dark about these concerns, say
activists, even as scientists are developing a clinical trial that could
finally offer answers.
New EMCDDA report shows heroin use in decline and patterns of drug use
shifting<http://www.aidsmap.com/Aggregator.ashx?type=bulletin&url=http%3a%2f%2fwww.emcdda.europa.eu%2fnews%2f2012%2f11&utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
from European Monitoring Centre for Drugs and Drug Addiction
Since the 1970s, heroin has held centre stage in Europe’s drugs scene and
is still responsible for the largest share of drug-related diseases and
deaths in the EU. But while heroin-related problems continue, they do so at
lower levels, says the EU drugs agency (EMCDDA).
UNITAID statement on Johnson & Johnson’s darunavir
announcement<http://www.aidsmap.com/Aggregator.ashx?type=bulletin&url=http%3a%2f%2fwww.unitaid.eu%2fresources%2fpress-centre%2fstatements%2f1051-unitaid-statement-on-johnson-johnson-s-darunavir-announcement&utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
from UNITAID press release <http://www.eatg.org/rss/feed/digest>
Johnson & Johnson’s announcement does not go nearly far enough due to its
limited geographical scope of just 64 countries.
New edition of
HATIP<http://www.aidsmap.com/Point-of-care-POC-diagnostics-are-essential-to-achieving-an-AIDS-free-generation-and-improving-outcomes-in-HIV-exposed-children/page/2559514/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
<http://www.aidsmap.com/Point-of-care-POC-diagnostics-are-essential-to-achieving-an-AIDS-free-generation-and-improving-outcomes-in-HIV-exposed-children/page/2559514/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
HIV & AIDS treatment in practice (HATIP) is our regular bulletin for people
working in resource-limited settings.
This 200th edition looks at point-of-care testing in the context of early
diagnosis and treatment of children.
Read more >><http://www.aidsmap.com/Point-of-care-POC-diagnostics-are-essential-to-achieving-an-AIDS-free-generation-and-improving-outcomes-in-HIV-exposed-children/page/2559514/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Infographic: HIV and the
liver<http://www.aidsmap.com/resources/Infographic-HIV-and-the-liver/page/2557952/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
<http://www.aidsmap.com/resources/Infographic-HIV-and-the-liver/page/2557952/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
The European Association for the Study of the Liver (EASL) is holding a
conference on HIV and the liver this month.
EASL and NAM worked together to produce an infographic, clearly setting out
some of the facts about HIV and the liver.
Download the infographic
>><http://www.aidsmap.com/resources/Infographic-HIV-and-the-liver/page/2557952/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
The HIV Justice
Network<http://www.aidsmap.com/The-HIV-Justice-Network/page/2559093/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
<http://www.aidsmap.com/The-HIV-Justice-Network/page/2559093/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
We're delighted to have been involved in the design and development of the
new HIV Justice Network website.
Find out more >><http://www.aidsmap.com/The-HIV-Justice-Network/page/2559093/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Fertility and conception<http://www.aidsmap.com/How-are-we-going-to-have-a-baby-Im-positive-and-youre-not/page/2541040/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
<http://www.aidsmap.com/How-are-we-going-to-have-a-baby-Im-positive-and-youre-not/page/2541040/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
In the latest issue of *HIV treatment update,* *Joanna Moss *of the African
Health Policy Network looks at conception and fertility guidelines and
services for people with HIV in the UK.
Read more >><http://www.aidsmap.com/How-are-we-going-to-have-a-baby-Im-positive-and-youre-not/page/2541040/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
UK HIV test finder<http://www.aidsmap.com/hiv-test-finder?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
<http://www.aidsmap.com/hiv-test-finder?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
We've recently launched a new UK *HIV test
finder<http://www.aidsmap.com/hiv-test-finder?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
*, containing over 700 services.
It's available on our
website<http://www.aidsmap.com/hiv-test-finder?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>,
through a free iPhone app <https://itunes.apple.com/us/app/id577199759> and
through a Facebook app <https://apps.facebook.com/hiv-test-finder/>.
More in the NAM blog
>><http://www.aidsmap.com/HIV-test-finder-a-new-tool-for-your-smartphone-and-Facebook/page/2553632/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
New from NAM<http://www.aidsmap.com/HIV-GPs-and-other-primary-care/page/2532783/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
<http://www.aidsmap.com/HIV-GPs-and-other-primary-care/page/2532783/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
This new booklet, *HIV, GPs & other primary
care*<http://www.aidsmap.com/HIV-GPs-other-primary-care/page/2521996/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>,
explains the services GPs offer, how this care fits with HIV specialist
care, and how to make the most of primary care services.
This resource is available in print and is part of our free booklet scheme,
which provides HIV information materials free to clinics and organisations
in the UK, please contact
us<http://www.aidsmap.com/contact?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>for
more information.
You can read this booklet on our
website<http://www.aidsmap.com/HIV-GPs-other-primary-care/page/2521996/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>,
where you can also download a pdf version, or view the pdf as a flipbook.
More in the NAM blog
>><http://www.aidsmap.com/HIV-GPs-and-other-primary-care/page/2532783/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
NAM is an award-winning, community-based organisation, which works from the
UK. We deliver reliable and accurate HIV information across the world to
HIV-positive people and to the professionals who treat, support and care
for them.
Make a donation, make a difference at
www.aidsmap.com/donate<http://www.aidsmap.com/donate?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
*For more details, please contact NAM*
tel: +44 (0)20 3242 0820
fax: +44 (0)20 3242 0839
email: info at nam.org.uk
web: www.aidsmap.com<http://www.aidsmap.com/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
*NAM Publications*
Registered office: 77a Tradescant Road, London, SW8 1XJ
Company limited by guarantee. Registered in England & Wales, number: 2707596
Registered charity, number: 1011220
To unsubscribe please visit:
http://www.aidsmap.com/page/1492854/<http://www.aidsmap.com/page/1492854/?type=x&utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.resist.ca/pipermail/viva/attachments/20121218/6b712338/attachment-0001.html>
More information about the Viva
mailing list